» Articles » PMID: 32259085

The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension

Overview
Specialty Biochemistry
Date 2020 Apr 8
PMID 32259085
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions worldwide. Currently, there are only four approved treatments for AD, which improve symptoms modestly. AD is believed to be caused by the formation of intercellular plaques and intracellular tangles in the brain, but thus far all new drugs which target these pathologies have failed clinical trials. New research highlights the link between AD and Type II Diabetes (T2D), and some believe that AD is actually a brain specific form of it termed Type III Diabetes (T3D). Drugs which are currently approved for the treatment of T2D, such as metformin, have shown promising results in improving cognitive function and even preventing the development of AD in diabetic patients. Recent studies shed light on the relationship between the brain and cardiovascular system in which the brain and heart communicate with one another via the vasculature to regulate fluid and nutrient homeostasis. This line of research reveals how the brain-heart axis regulates hypertension and diabetes, both of which can impact cognitive function. In this review we survey past and ongoing research and clinical trials for AD, and argue that AD is a complex and systemic disorder which requires comprehensive approaches beyond the brain for effective prevention and/or treatment.

Citing Articles

Effects of physical multimorbidity on cognitive decline trajectories among adults aged 50 years and older with different wealth status: a 17-year population-based cohort study.

Chen C, Zhang S, Huang N, Zhang M, Fu J, Guo J Glob Ment Health (Camb). 2025; 11():e131.

PMID: 39777001 PMC: 11704386. DOI: 10.1017/gmh.2024.141.


Causal associations between hypertension and abnormal brain cortical structures: Insights from a bidirectional Mendelian randomization study.

Fang T, Wang X, Wang Y, Zheng X, Huangfu N Int J Cardiol Cardiovasc Risk Prev. 2025; 24:200354.

PMID: 39760130 PMC: 11696852. DOI: 10.1016/j.ijcrp.2024.200354.


Cross-disease modeling of peripheral blood identifies biomarkers of type 2 diabetes predictive of Alzheimer's disease.

Ball B, Park J, Proctor E, Brubaker D bioRxiv. 2024; .

PMID: 39713369 PMC: 11661382. DOI: 10.1101/2024.12.11.627991.


Integrating Comorbidity Knowledge for Alzheimer's Disease Drug Repurposing using Multi-task Graph Neural Network.

Lin K, Hsieh K, Jiang X, Kim Y AMIA Jt Summits Transl Sci Proc. 2023; 2023:378-387.

PMID: 37350918 PMC: 10283123.


Depression as a cardiovascular disorder: central-autonomic network, brain-heart axis, and vagal perspectives of low mood.

Valenza G Front Netw Physiol. 2023; 3:1125495.

PMID: 37260560 PMC: 10228690. DOI: 10.3389/fnetp.2023.1125495.


References
1.
Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A . Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009; 70(6):922-31. View

2.
Hebert L, Weuve J, Scherr P, Evans D . Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013; 80(19):1778-83. PMC: 3719424. DOI: 10.1212/WNL.0b013e31828726f5. View

3.
Risner M, Saunders A, Altman J, Ormandy G, Craft S, Foley I . Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006; 6(4):246-54. DOI: 10.1038/sj.tpj.6500369. View

4.
Doody R, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013; 369(4):341-50. DOI: 10.1056/NEJMoa1210951. View

5.
Nakagawa P, Sigmund C . How Is the Brain Renin-Angiotensin System Regulated?. Hypertension. 2017; 70(1):10-18. PMC: 5511499. DOI: 10.1161/HYPERTENSIONAHA.117.08550. View